What makes the release of Gersey’s book a concern: Asahi Shimbun journalists’ demonstrations highlight the real importance of the role of newspaper reporters in serving society.

The trigger was a book published by the former Asahi Shimbun Dubai bureau chief

There is a heated debate among media people as to whether a retired reporter should write about what he covered in his previous job.

It was triggered by Yoshiyuki Ito, the former head of the Asahi Shimbun’s Dubai bureau.Villain Infiltration 300 Days Dubai Garthy Gang(Kodansha) is a book.

Yoshikazu Azumaya, also known as Garthy, is a former member of the House of Councilors and is on the international wanted list. Mr. Ito, who interviewed Garthy in April 2022 when he was the head of the Dubai bureau, conflicted with the Asahi Shimbun over the publication of the interview and retired from the company in August of the same year. After that, he continued his own research and wrote this book.

I heard from an acquaintance in the publishing industry that “that book seems to be selling quite well,” so I was curious. However, I had no interest in Garthy, so I didn’t pick it up.

However, I was surprised to hear that the Asahi Shimbun lodged a protest against Mr. Ito, the author of “Akutou,” and the publisher, Kodansha.

The saying, “Don’t write about what you interviewed while you were working, even if you quit.”

On March 28, the Asahi Shimbun posted on its website, “We protested the unauthorized use of interview information.” According to Asahi’s site, the statement is as follows.

Journalist Declaration. Asahi Shimbun (Photo: MIKI Yoshihito/CC-BY-2.0/Wikimedia Commons

According to the rules of employment, works such as articles written by retirees as part of their duties while they were employed are deemed to be works for employment, the copyright of which belongs to the head office, regardless of whether they were published in newspapers, etc., and unauthorized use is permitted. Is not …

Read more:  what awaits humanity - UNIAN

In addition, the description of this book includes a lot of information that Mr. Ito interviewed during his tenure. This information is subject to confidentiality obligations in the employment contract with the head office. Employment regulations stipulate that employees of the head office must not divulge confidential information that they have learned in the course of their work to others without justifiable reason, not only during employment but even after retirement. ”

To summarize, the Asahi Shimbun claims:

(1) The company owns the copyright of the manuscript written by the reporter, regardless of whether it was published in the newspaper or not.
(2) Don’t divulge what you interviewed during your tenure even after you retire “without justifiable reason”.

In short, even if you quit, don’t write about what you covered while you were working.

Related News

Give a title to rank high in google for this content

The pharmaceutical company announced that its vaccine was 85% effective in preventing severe cases of RSV in older adults.

Today respiratory diseases have experienced an increase in cases in both children and adults and the respiratory syncytial virus (VRS) is one of the most common. This disease can have mild or severe symptoms, depending on each patient. The United States Food and Drug Administration (FDA) has taken a big step by approving this Wednesday the use of the Pfizer vaccine to treat RSV in older adults.

It is the second RSV vaccine the FDA has approved this month. The pharmaceutical GlaxoSmithKline It also got the green light from the regulator to market its own serum to treat the disease in older adults, The Hill reports.

RSV usually causes mild symptoms in healthy children and adults, but for the elderly it can lead to complications.

Between 60,000 and 160,000 people over the age of 65 are hospitalized each year for the disease in USA. Between 6,000 and 13,000 end up dying, according to The Hill.

In August, Pfizer announced that its vaccine was 85% effective in preventing severe cases of RSV in older adults.

In addition to the vaccine for the elderly, called Abrysvothe FDA is also considering approving Pfizer’s serum for pregnant women, which seeks to prevent RSV cases in babies.

According to the criteria of The Trust Project

Know more

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Give a title to rank high in google for this content

The pharmaceutical company announced that its vaccine was 85% effective in preventing severe cases of RSV in older adults.

Today respiratory diseases have experienced an increase in cases in both children and adults and the respiratory syncytial virus (VRS) is one of the most common. This disease can have mild or severe symptoms, depending on each patient. The United States Food and Drug Administration (FDA) has taken a big step by approving this Wednesday the use of the Pfizer vaccine to treat RSV in older adults.

It is the second RSV vaccine the FDA has approved this month. The pharmaceutical GlaxoSmithKline It also got the green light from the regulator to market its own serum to treat the disease in older adults, The Hill reports.

RSV usually causes mild symptoms in healthy children and adults, but for the elderly it can lead to complications.

Between 60,000 and 160,000 people over the age of 65 are hospitalized each year for the disease in USA. Between 6,000 and 13,000 end up dying, according to The Hill.

In August, Pfizer announced that its vaccine was 85% effective in preventing severe cases of RSV in older adults.

In addition to the vaccine for the elderly, called Abrysvothe FDA is also considering approving Pfizer’s serum for pregnant women, which seeks to prevent RSV cases in babies.

According to the criteria of The Trust Project

Know more

Editor's Pick